| __timestamp | Supernus Pharmaceuticals, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 72471000 | 5078000000 |
| Thursday, January 1, 2015 | 89204000 | 4717000000 |
| Friday, January 1, 2016 | 106010000 | 5096000000 |
| Sunday, January 1, 2017 | 137905000 | 4986000000 |
| Monday, January 1, 2018 | 159888000 | 4214000000 |
| Tuesday, January 1, 2019 | 158425000 | 3806000000 |
| Wednesday, January 1, 2020 | 200677000 | 3671000000 |
| Friday, January 1, 2021 | 304759000 | 3528000000 |
| Saturday, January 1, 2022 | 377221000 | 3445000000 |
| Sunday, January 1, 2023 | 336361000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Cracking the code
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Teva Pharmaceutical Industries Limited and Supernus Pharmaceuticals, Inc. have shown contrasting strategies in optimizing these costs. Teva, a global leader, has seen a significant reduction in SG&A expenses, dropping from 5.08 billion in 2014 to 3.50 billion in 2023, a 31% decrease. This reflects their strategic cost-cutting measures amidst industry challenges. Meanwhile, Supernus, a smaller player, has increased its SG&A spending from 72 million to 336 million, a 366% rise, indicating aggressive investment in growth and market expansion. This divergence highlights the different paths companies can take in managing operational costs, with Teva focusing on efficiency and Supernus on expansion. Understanding these strategies offers valuable insights into the financial health and strategic priorities of these pharmaceutical giants.
Operational Costs Compared: SG&A Analysis of argenx SE and Supernus Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited vs Viking Therapeutics, Inc.: SG&A Expense Trends
Teva Pharmaceutical Industries Limited vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Bausch Health Companies Inc. Trends and Insights
Who Generates Higher Gross Profit? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Teva Pharmaceutical Industries Limited vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs MiMedx Group, Inc.
Operational Costs Compared: SG&A Analysis of Exelixis, Inc. and Supernus Pharmaceuticals, Inc.
HUTCHMED (China) Limited vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Supernus Pharmaceuticals, Inc. and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Supernus Pharmaceuticals, Inc. and Xencor, Inc.